• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

VPNW.com

virtual publishing network

  • About
  • Sponsored Post
  • Make a Contribution
  • Contact

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

July 7, 2021 By admin Leave a Comment

mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic

mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages

Moderna’s vision is to develop a respiratory vaccine for the adult and elderly populations combining seasonal flu, COVID-19 variant booster and RSV

CAMBRIDGE, Mass. – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Company’s quadrivalent seasonal influenza mRNA vaccine candidate.

This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of mRNA-1010, Moderna’s seasonal influenza vaccine candidate in healthy adults 18 years and older in the U.S. The Company intends to enroll approximately 180 participants in the study. mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic and targets lineages recommended by the World Health Organization (WHO) for the prevention of influenza, including seasonal influenza A H1N1, H3N2 and influenza B Yamagata and Victoria.

“We are pleased to have begun this Phase 1/2 study of mRNA-1010, our first mRNA seasonal flu vaccine candidate to enter the clinic. We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy. We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evolution of respiratory viruses, such as influenza, SARS-CoV-2 and RSV. Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses. We look forward to advancing our core modality of prophylactic mRNA vaccines so that we can continue to make an impact on global public health.”

Seasonal flu (type A and type B) epidemics occur seasonally and vary in severity each year, causing respiratory illnesses and placing substantial burden on healthcare systems. The WHO estimates approximately 3-5 million severe cases of flu each year globally1, and 290,000-650,000 flu-related respiratory deaths. Approximately 8% of the U.S. population experiences symptoms from flu each year2. In the U.S., the estimated average economic burden of flu is approximately $11 billion per year3.

Current flu vaccines are only approximately 40-60% effective and their formulation is decided 6-9 months before the vaccines are intended to be used. Egg-based vaccine production, the process used for the majority of currently licensed influenza vaccines, also has the potential to cause unintended antigenic change to the vaccine virus. Moderna plans to explore potential combination vaccines against flu, SARS-CoV-2, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The Company’s overarching seasonal influenza program will aim to evaluate multiple candidates exploring different antigen combinations against seasonal influenza viruses in the clinic.

About Moderna
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

1 https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2 https://www.cdc.gov/flu/about/keyfacts.htm
3 https://pubmed.ncbi.nlm.nih.gov/29801998/

Related

Filed Under: News Tagged With: mRNA

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Opinion

An Epic Heist Gone Wrong: The 400 airplanes Russia seized after the war in Ukraine
ICYMI: Rubio: A Century of Misery for the Chinese Communist Party
Russia’s participation on the UN HRC is a farce
Putin’s Distorted Reality
There is now a business case for ramping up hydrogen
Chinese surgeons perform organ extractions from alive people
Russia’s Invasion of Ukraine: Overview of U.S. Sanctions and Other Responses

Press Media Release

Clarivate Names World’s Leading Journals with the 2022 Journal Citation Reports
Adorama Business Solutions Launches Federal Government Purchasing Portal
Bezos Earth Fund Announces First Commitments to Marine Protection at UN Ocean Conference
Russia is now just hours away from its first foreign default
How are key trends shaping marketing and public relations?
EPPA : New Study Shows That Making Reusable Containers for Takeaway Obligatory Will Undermine the EU’s Environmental Goals
SYSTECH is to Exhibit Fully Integrated Container and Fleet Tracking Solutions in Mexico

Secondary Sidebar

GameTech Market

Paysafe to Enable Online Cash Payments on Microsoft Store on Xbox
The pandemic led to a year of strong videogame sales
SIGGRAPH 2020 to Demo Real-time, Gaming Innovations During Virtual Conference
Go Behind the Year’s Biggest Visual Effects Productions During SIGGRAPH 2020 With ‘Making Of’ Sessions and Talks, 17–28 August, 2020
Logitech G Introduces G915 TKL, a More Compact Tenkeyless Gaming Keyboard
DigiNation will launch the metaverse game Babel and ecosystem products based on iOS and Android
Pepper Esports Inc, leading esports tournament software provider, announces new tournament platform to enable gamers to compete from home during the COVID-19 pandemic
China’s 3-hours-per-week video game restriction for minors
Helix Helps Mana Deliver Embedded Banking Solutions Tailored for Gamers
Game On Announces Marie-Hélène Weiss as Head of Production

Footer

Recent Posts

  • As a technical writer, it’s pretty common to do the thing you’re documenting
  • Most Platforms Fail
  • Adaptability Paradox
  • Fear holds back innovation efforts
  • Technology Digest
  • Forward-thinking companies are moving towards industry-specific marketing strategy
  • What did the latest consumer survey find about streaming services?
  • Cloudflare suffered an outage that affected global Internet traffic
  • AI-based transcription tools have made one particularly tiresome aspect of journalism far easier
  • THE NEW AGE OF TECH TALENT: EXPERIS RELEASES NEW REPORT SHOWING ‘SOFT SKILLS ARE THE NEW POWER SKILLS’

Media Partners

  • Pixel Effect
  • Digital Market
  • Briefly
  • OPINT
  • Exclusive
  • S3H
  • Domain Aftermarkets

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Domain Market Research
  • Domain Name for Business

Copyright © 2018 VPNW.com

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT